

# Cancer Bio Course

Session 3: From observation to experimentation. Cancer evolution and the role of the tumor microenvironment.

August 21<sup>st</sup>, 2024



Memorial Sloan Kettering  
Cancer Center

**Pablo Sánchez Vela, MD**  
Senior Research Scientist  
Human Oncology and Pathogenesis Program  
[sanchezp@mskcc.org](mailto:sanchezp@mskcc.org)

# Paper discussion

## Article


# Lung adenocarcinoma promotion by air pollutants

<https://doi.org/10.1038/s41586-023-05874-3>

Received: 17 June 2022

Accepted: 21 February 2023


Published online: 5 April 2023

 Check for updates


William Hill<sup>1,126</sup>, Emilia L. Lim<sup>1,2,126,127</sup>, Clare E. Weeden<sup>1,126</sup>, Claudia Lee<sup>1,2,3</sup>, Marcellus Augustine<sup>1,2,3,4</sup>, Kezhong Chen<sup>2,5</sup>, Feng-Che Kuan<sup>6,7</sup>, Fabio Marongiu<sup>8,9</sup>, Edward J. Evans Jr<sup>8</sup>, David A. Moore<sup>12,10</sup>, Felipe S. Rodrigues<sup>11</sup>, Oriol Pich<sup>1</sup>, Bjorn Bakker<sup>1</sup>, Hongui Cha<sup>2,12</sup>, Renelle Myers<sup>13</sup>, Febe van Maldegem<sup>14,15</sup>, Jesse Boumelha<sup>14</sup>, Selvaraju Veeriah<sup>2</sup>, Andrew Rowan<sup>1</sup>, Cristina Naceur-Lombardelli<sup>2</sup>, Takahiro Karasaki<sup>1,2,16</sup>, Monica Sivakumar<sup>2</sup>, Swapnanil De<sup>2</sup>, Deborah R. Caswell<sup>1</sup>, Ai Nagano<sup>1,2</sup>, James R. M. Black<sup>2,17</sup>, Carlos Martínez-Ruiz<sup>2,17</sup>, Min Hyung Ryu<sup>18</sup>, Ryan D. Huff<sup>18</sup>, Shijia Li<sup>18</sup>, Marie-Julie Favé<sup>19</sup>, Alastair Magness<sup>1,2</sup>, Alejandro Suárez-Bonnet<sup>20,21</sup>, Simon L. Priestnall<sup>20,21</sup>, Margreet Luchtenborg<sup>22,23</sup>, Katrina Lavelle<sup>22</sup>, Joanna Pethick<sup>22</sup>, Steven Hardy<sup>22</sup>, Fiona E. McRonal<sup>22</sup>, Meng-Hung Lin<sup>24</sup>, Clara I. Troccoli<sup>8,25</sup>, Moumita Ghosh<sup>26</sup>, York E. Miller<sup>26,27</sup>, Daniel T. Merrick<sup>28</sup>, Robert L. Keith<sup>26,27</sup>, Maise Al Bakir<sup>1,2</sup>, Chris Bailey<sup>1</sup>, Mark S. Hill<sup>1</sup>, Lao H. Saal<sup>29,30</sup>, Yilun Chen<sup>29,30</sup>, Anthony M. George<sup>29,30</sup>, Christopher Abbosh<sup>2</sup>, Nnennaya Kanu<sup>2</sup>, Se-Hoon Lee<sup>2</sup>, Nicholas McGranahan<sup>2,17</sup>, Christine D. Berg<sup>31</sup>, Peter Sasieni<sup>32</sup>, Richard Houlston<sup>33</sup>, Clare Turnbull<sup>33</sup>, Stephen Lam<sup>13</sup>, Philip Awadalla<sup>19</sup>, Eva Grönroos<sup>1</sup>, Julian Downward<sup>14</sup>, Tyler Jacks<sup>34,35</sup>, Christopher Carlsen<sup>18</sup>, Ilaria Malanchi<sup>19</sup>, Allan Hackshaw<sup>26</sup>, Kevin Litchfield<sup>2,4</sup>, TRACERx Consortium\*, James DeGregori<sup>8,127</sup>, Mariam Jamal-Hanjan<sup>2,16,37,127</sup> & Charles Swanton<sup>1,2,37,127</sup>✉

# Paper discussion

- **Explanation of the question under research** - *why did they decide to do this?*
- **Discussion figure by figure** – *is this paper not as good as authors think?:*
  - What is the point of each figure/panel?
  - Are there any missing experimental conditions?
  - Are results interpretable?
  - Do the results support the conclusions by the authors?
  - Would you have done anything differently?
  - Are there any missing experiments?
  - What are the limitations of the work?
  - What experiments could be done as a follow-up to the paper?






# Fig. 1: Exploring the association between cancer and air pollution.




# Basics about preclinical validation

## Correlation versus causation




# Basics about preclinical validation

## Preclinical models



Cell line (2D system)



Organoids (3D system)



## *In vitro* models



## *In vivo* models

Patient-derived xenografts (3D system)

Genetically engineered mouse models (GEMMs)



Cell line xenografts (3D system)

# Basics about preclinical validation

Some **pros** and **cons**

## *In vitro* models

### Cell lines

- Very easy to work with, quicker and cheaper
- Allow easy genetic manipulation
- Very simplified model, 2D, no tumor microenvironment (TME)

### Organoids

- Relatively easy to work with, quick and cheap.
- Allow relatively easy genetic manipulation
- 3D system that reproduces fairly well the behavior of tumors
- Simplified model, no TME

## *In vivo* models

### Patient-derived xenografts (PDXs)

- Reproduce very well the behavior of tumors (specially in treatment response)
- As close as you can get to an actual human tumor
- No TME
- Expensive, time-consuming
- Very difficult genetic manipulation

### GEMMs

- Can reproduce well the biology of human tumors
- TME
- Expensive and time-consuming
- **Not human!**

### Cell line xenografts

- Allow easy genetic manipulation (cell line) and in vivo study (xenograft)
- No TME
- Derived from a very simplified model (cell line)

# GEMM





Figure 2: Cre-expressing and loxP-expressing mice are separately engineered, and then crossed to generate Cre-lox mice that express both Cre and a floxed gene segment. These mice can undergo recombination of the floxed gene segment to create knockouts or knockins. Image from Matthias Zepper.



# GEMM control

## a LoxP-mediated gene inactivation and activation




## b Tet-mediated gene inactivation and activation




Nature Reviews | Cancer

# Fig. 2: PM promotes lung tumorigenesis.




# Fig. 3: Increased progenitor-like ability of EGFR mutant cells following PM exposure.





# The importance of context

## The Reductionist View



## A Heterotypic Cell Biology











Fig. 4: Mutational landscapes of healthy lung tissue.



# Study design, DNA analysis & epidemiology.

A





**Thanks for your attention!**

**Any questions?**



Memorial Sloan Kettering  
Cancer Center